The cardioprotective effect of the iron chelator dexrazoxane (ICRF-187) on anthracycline-mediated cardiotoxicity

Redox Report

Volumn 5, Issue 6, 2000, Pages 317-324

  Kwok, J C ^a   Richardson, D R ^a  

^a HEART RESEARCH INSTITUTE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

1,2 PROPANEDIAMINE N,N' DIACETAMIDE N,N' DIACETIC ACID; ANTHRACYCLINE; BINDING PROTEIN; CYCLOPHOSPHAMIDE; DEFERIPRONE; DEFEROXAMINE; DOXORUBICIN; DOXORUBICINOL; EDETIC ACID; FLUOROURACIL; FREE RADICAL; IRON; IRON CHELATING AGENT; IRON COMPLEX; IRON REGULATORY FACTOR; PLACEBO; RAZOXANE; REACTIVE OXYGEN METABOLITE; REGULATOR PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CARDIOTOXICITY; CHELATION THERAPY; CHEMICAL REACTION; CLINICAL TRIAL; COMPLEX FORMATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG HYDROLYSIS; DRUG MECHANISM; DRUG STRUCTURE; HEART MUSCLE CELL; HEART PROTECTION; HOMEOSTASIS; HUMAN; HUMAN CELL; HUMAN TISSUE; IRON CHELATION; IRON METABOLISM; IRON TRANSPORT; METAL BINDING; MOUSE; NONHUMAN; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RAT; REVIEW;

ANIMALS; ANTHRACYCLINES; ANTINEOPLASTIC AGENTS; CARDIOVASCULAR AGENTS; CHELATING AGENTS; HEART; HUMANS; RAZOXANE;

EID: 0034523687     PISSN: 13510002     EISSN: None     Source Type: Journal    
DOI: 10.1179/135100000101535898     Document Type: Review

References (58)

1. Chemotherapeutic agents: Cancer chemotherapy
2. A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin
3. The anthracyclines: Will we ever find a better doxorubicin?
4. Cytoprotective agents for anthracyclines
5. Speciation studies of adriamycin, quelamycin, and their metal complexes
6. Adriamycin and its iron(III) and copper(II) complexes
7. Role of iron in anthracycline cardiotoxicity: New tunes for an old song?
8. Secondary alcohol metabolites mediate iron delocalization in cytosolic fractions of myocardial biopsies exposed to anticancer anthracyclines
9. The secondary alcohol metabolite of doxorubicin irreversibly inactivates aconitase/iron regulatory protein-1 in cytosolic fractions from human myocardium
10. Doxorubicin cardiotoxicity: Analysis of prevailing hypotheses
11. Mitochondrial NADH dehydrogenase-catalyzed oxygen radical production by adriamycin, and the relative iminodaunorubicin
12. Effect of anthracycline antibiotics on oxygen radical formation in rat heart
13. The role of free radical formation in the cardiotoxicity of anthracycline
14. The inactivation of Fe-S cluster containing hydro-lyases by superoxide
15. Cell-permeable superoxide dismutase and glutathione peroxidase mimetics afford superior protection against doxorubicin-induced cardiotoxicity: The role of reactive oxygen and nitrogen intermediates
16. The role of iron in doxorubicin-induced cardiomyopathy
17. Cardiac disease induced by chronic adriamycin administration in dogs and an elevation of vitamin E and selenium as cardioprotectants
18. A randomized controlled trial assessing the prevention of doxorubicin in cardiomyopathy by N-acetylcysteine
19. The iron(III)-adriamycin complex inhibits cytochrome c oxidase before its inactivation
20. Characterization of the cycle of iron-mediated electron transfer from adriamycin to molecular oxygen
21. Dexrazoxane (ICRF-187)
22. Clinical pharmacology of dexrazoxane
23. An HPLC and spectrophotometric study of the hydrolysis of ICRF-187 ((+)-1,2-bis(3,5-dioxopiperazinly-1-yl)propane) and its open-ring hydrolysis intermediates
24. Ferrous ion strongly promotes the ring opening of the hydrolysis intermediates of the antioxidant cardioprotective agent dexrazoxane (ICRF-187)
25. The one-ring open hydrolysis product intermediates of the cardioprotective agent ICRF-187 (dexrazoxane) displace iron from iron-anthracycline complexes
26. The iron(III) and copper(II) complexes of adriamycin promote the hydrolysis of the cardioprotective agent ICRF-187 ((+)-1,2-bis(3,5-dioxopiperazinly-1-yl)propane)
27. Inhibition of anthracycline semiquinone formation by ICRF-187 (dexrazoxane) in cells
28. The removal of metal ions from transferrin, ferritin and ceruloplasmin by the cardioprotective agent ICRF-187 [(+)-1,2-bis(3,5-dioxopiperazinly-1-yl)propane] and its hydrolysis product ADR-925
29. Site specificity of iron removal from transferrin by α-ketohydroxypyridone chelators
30. The study of iron mobilisation from transferrin using alpha-ketohydroxy heteroaromatic chelators
31. Strategies for reduction of anthracycline cardiac toxicity
32. Methods of reducing the cardiotoxicity of anthracycline
33. Preclinical models of cardiac protection and testing for effects of dexrazoxane on doxorubicin antitumor effects
34. Dose-response relationship of dexrazoxane for prevention of doxorubicin-induced cardiotoxicity in mice, rats, and dogs
35. Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer
36. ICRF-187 (ICRF) prevents doxorubicin (DOX) cardiotoxicity (CTOX): Results of a randomized clinical trial
37. Randomized trial of the cardioprotective agent ICRF-187 in pediatric sarcoma patients treated with doxorubicin
38. Ameliorating anthracycline cardiotoxicity in children with cancer: Clinical trials with dexrazoxane
39. Cardioprotection by ICRF-187 against high dose anthracycline toxicity in children with malignant disease
40. ICRF-187 (Cardioxane) protection against doxorubicin induced cardiomyopathy in paediatric osteosarcoma patients
41. The molecular mechanisms of the metabolism and transport of iron in normal and neoplastic cells
42. Molecular control of vertebrate iron metabolism: mRNA-based regulatory circuits operated by iron, nitric oxide, and oxidative stress
43. Iron regulatory proteins, iron responsive elements and iron homeostasis
44. Transferrin and iron distribution in subcellular fractions of K562 cells in early stages of transferrin endocytosis
45. Distribution of iron in reticulocytes after inhibition of heme synthesis with succinylacetone: Examination of the intermediates involved in iron metabolism
46. Positional cloning of zebrafish ferroportin 1 identifies a conserved vertebrate iron exporter
47. Cloning and characterization of a mammalian proton-coupled metal-ion transporter
48. Iron(II) is a modulator of ryanodine-sensitive calcium channels of cardiac muscle sarcoplasmic reticulum
49. Early anthracycline cardiotoxicity
50. Human Ferritin (HLF) as iron source for lipid peroxidation by adriamycin (adr)
51. Adriamycin-dependent release of iron from microsomal membranes
52. Modulation of transferrin receptor expression by dexrazoxane (ICRF-187) via activation of iron regulatory protein
53. Modulation of the RNA-binding activity of a regulatory protein by iron in vitro: Switching between enzymatic and genetic function
54. The potential of analogues of the pyridoxal isonicotinoyl hydrazone class as effective anti-proliferative agents III: The effect of the ligands on molecular targets involved in proliferation
55. Prevention of doxorubicin-induced killing of MCF-7 human breast cancer cells by oxygen radical scavengers and iron chelating agents
56. Anthracycline toxicity is potentiated by iron and inhibited by deferoxamine. Studies in rat heart cells in culture
57. The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective anti-proliferative agents
58. The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents II. The mechanism of action 2-hydroxy-1-naphthylaldehyde benzoyl hydrazone